Compare FEIM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | MYGN |
|---|---|---|
| Founded | 1961 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 444.2M |
| IPO Year | 1994 | 1996 |
| Metric | FEIM | MYGN |
|---|---|---|
| Price | $68.32 | $4.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $51.50 | $7.64 |
| AVG Volume (30 Days) | 143.8K | ★ 1.6M |
| Earning Date | 03-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | $69,811,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $21.73 | $5.45 |
| P/E Ratio | $176.63 | ★ N/A |
| Revenue Growth | ★ 26.30 | 2.33 |
| 52 Week Low | $18.63 | $3.53 |
| 52 Week High | $76.07 | $8.59 |
| Indicator | FEIM | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 57.61 |
| Support Level | $43.53 | $4.55 |
| Resistance Level | $76.07 | $5.42 |
| Average True Range (ATR) | 5.11 | 0.27 |
| MACD | 0.10 | 0.12 |
| Stochastic Oscillator | 62.83 | 83.53 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.